Buspirone augmentation of fluoxetine in obsessive-compulsive disorder.
Eleven obsessive-compulsive patients underwent a prospective open-label trial of fluoxetine monotherapy followed by buspirone augmentation. The combination therapy was statistically superior to fluoxetine monotherapy. The results point to the importance of the 5-HT1a receptor in obsessive-compulsive disorder.
Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH.
P J
PJ
Markovitz
S J
SJ
Stagno
J R
JR
Calabrese
D000328:Adult; D002065:Buspirone / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000523:psychology; D011446:Prospective Studies; D011985:Receptors, Serotonin / Q000187:drug effects
D011985:Receptors, Serotonin; D005473:Fluoxetine; D002065:Buspirone